Newsroom

LONDRES--(BUSINESS WIRE)--  Prokarium annonce des résultats intermédiaires positifs de l’essai de phase 1/1b PARADIGM-1 évaluant ZH9 chez des patients atteints d’un cancer de la vessie non invasif sur le plan musculaire, avec une excellente tolérance et une efficacité précoce encourageante   Prokarium, société biopharmaceutique au stade clinique pionnière dans les immunothérapies bactériennes pour le traitement des tumeurs solides, a annoncé aujourd’hui des résultats de sécurité et d’efficacité...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100® Moderate Buffer UCITS ETF - March 18.05.2026 QMAR.LN IE0006S0EBF2 50,002.00 USD 1,233,973.10 24.678  ...

LONDRES--(BUSINESS WIRE)--Prokarium, una empresa biofarmacéutica en fase clínica pionera en inmunoterapias bacterianas para el tratamiento de tumores sólidos, anunció hoy los resultados de seguridad y eficacia antitumoral de una revisión interina del ensayo PARADIGM-1 fase 1/1b en curso de ZH9 en pacientes con cáncer de vejiga sin invasión muscular (NMIBC). El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá s...

LONDON--(BUSINESS WIRE)--Prokarium, ein biopharmazeutisches Unternehmen im klinischen Stadium, das Pionierarbeit bei bakteriellen Immuntherapien zur Behandlung solider Tumoren leistet, gab heute die Ergebnisse zur Sicherheit und Antitumorwirksamkeit aus einer Zwischenauswertung der laufenden Phase-1/1b-Studie PARADIGM-1 mit ZH9 bei Patienten mit nicht-muskelinvasivem Blasenkrebs (NMIBC) bekannt. Diese Daten wurden im Rahmen eines mündlichen Vortrags auf der Jahrestagung der American Urological...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 18.05.2026 FTAI IE000YIQZ0H6 200,002.00 USD 5,726,564.65 28.633  ...

DALLAS & AMSTERDAM--(BUSINESS WIRE)--o9, a leading software company that is powering enterprise planning and decisioning models across 30-plus industry verticals with its groundbreaking, AI-powered Digital Brain platform, today announced that it will host aim10x Europe 2026 on June 4 in Amsterdam. Featuring a roster of high-profile speakers from premium brands across Europe, the summit will bring together hundreds of executives, transformation leaders, and practitioners to learn how next-genera...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 18.05.2026 MJUN LN IE000CO3P697 150,002.00 USD 3,789,297.58 25.262  ...

SAN FRANCISCO--(BUSINESS WIRE)--Subsea cable operator Seaborn Networks saves ~$4M annually with Kentik by shifting transit traffic to peering and optimizing costs....

CHARLEVOIX, Mich.--(BUSINESS WIRE)--BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 18.05.2026 QDEC.LN IE000GAKWFA7 450,002.00 USD 10,841,287.27 24.092  ...